Multiple myeloma: my highlights at ASH 2020

Summary The meeting focused in particular on new strategies such as chimeric antigen receptor (CAR)-T cells and bispecific antibodies. Updates of clinical trials regarding induction treatment transplantable non-transplantable status were presented. Furthermore, minimal residual disease negativity (MRD) or, other words, a characterized by no measurable disease, using standardized multicolor-flow cytometry or next-generation sequencing techniques becomes increasingly important an endpoint trials. A subjectively assessed overview the current contributions to multiple myeloma is given here.